DE69530325D1 - Aerosol-arzneiformulierungen - Google Patents

Aerosol-arzneiformulierungen

Info

Publication number
DE69530325D1
DE69530325D1 DE69530325T DE69530325T DE69530325D1 DE 69530325 D1 DE69530325 D1 DE 69530325D1 DE 69530325 T DE69530325 T DE 69530325T DE 69530325 T DE69530325 T DE 69530325T DE 69530325 D1 DE69530325 D1 DE 69530325D1
Authority
DE
Germany
Prior art keywords
drug formulations
aerosol drug
aerosol
formulations
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69530325T
Other languages
English (en)
Other versions
DE69530325T2 (de
Inventor
Kjell Baeckstroem
Magnus Dahlbaeck
Ann Johansson
Goeran Kaellstrand
Elisabet Lindqvist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26662196&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69530325(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9404469A external-priority patent/SE9404469D0/xx
Priority claimed from SE9502452A external-priority patent/SE9502452D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69530325D1 publication Critical patent/DE69530325D1/de
Application granted granted Critical
Publication of DE69530325T2 publication Critical patent/DE69530325T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69530325T 1994-12-22 1995-12-19 Aerosol-arzneiformulierungen Expired - Lifetime DE69530325T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9404469 1994-12-22
SE9404469A SE9404469D0 (sv) 1994-12-22 1994-12-22 Aerosol formulations
SE9502452A SE9502452D0 (sv) 1995-07-06 1995-07-06 Aerosol formulations
SE9502452 1995-07-06
PCT/SE1995/001542 WO1996019198A1 (en) 1994-12-22 1995-12-19 Aerosol drug formulations

Publications (2)

Publication Number Publication Date
DE69530325D1 true DE69530325D1 (de) 2003-05-15
DE69530325T2 DE69530325T2 (de) 2004-02-19

Family

ID=26662196

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530325T Expired - Lifetime DE69530325T2 (de) 1994-12-22 1995-12-19 Aerosol-arzneiformulierungen

Country Status (24)

Country Link
US (1) US6932962B1 (de)
EP (1) EP0806940B1 (de)
JP (2) JP4155594B2 (de)
KR (1) KR100428914B1 (de)
CN (1) CN1088580C (de)
AR (1) AR002014A1 (de)
AT (1) ATE236617T1 (de)
BR (1) BR9510510A (de)
CA (1) CA2206782C (de)
CZ (1) CZ288146B6 (de)
DE (1) DE69530325T2 (de)
EE (1) EE9700138A (de)
FI (1) FI972655A (de)
HU (1) HUT77775A (de)
IL (1) IL116460A (de)
IS (1) IS4499A (de)
MX (1) MX9704550A (de)
MY (1) MY131733A (de)
NO (1) NO318229B1 (de)
NZ (1) NZ298169A (de)
PL (1) PL320856A1 (de)
SK (1) SK81197A3 (de)
TR (1) TR199501673A1 (de)
WO (1) WO1996019198A1 (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4003270A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
GB9620187D0 (en) * 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9626960D0 (en) 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
AU718967B2 (en) * 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
JP2005281315A (ja) * 1997-07-02 2005-10-13 Aventis Pharmaceuticals Holdings Inc 水性薬理組成物
EP1019023B1 (de) * 1997-09-29 2003-05-07 Inhale Therapeutic Systems, Inc. In verneblern verwendbare, stabilisierte zubereitungen
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999025786A1 (en) * 1997-11-18 1999-05-27 Alliedsignal Inc. Hydrofluorocarbon refrigerants
SE9704644D0 (sv) * 1997-12-12 1997-12-12 Astra Ab New use
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
ES2141049B1 (es) * 1998-03-11 2000-10-16 Aldo Union S A Lab Formulaciones farmaceuticas en aerosol que contienen trigliceridos de cadena media como surfactantes.
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
EP1100465B1 (de) 1998-07-24 2004-11-24 Jago Research Ag Medizinische aerosolformulierungen
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
SE9804003D0 (sv) 1998-11-23 1998-11-23 Astra Ab A method of producing drug particles
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US6565833B1 (en) 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6464959B1 (en) 2000-05-01 2002-10-15 Aeropharm Technology Incorporated Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6468507B1 (en) 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ME00220B (me) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
EP2298279B1 (de) 2000-11-30 2018-11-14 Vectura Limited Pharmazeutische Zusammensetzungen zur Inhalation
AU2002222118A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
ES2334642T5 (es) 2000-11-30 2016-03-07 Vectura Limited Partículas para usar en una composición farmacéutica
JP2004526674A (ja) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート 液体処方物中における生体分子の安定化のための方法
SE0004750D0 (sv) * 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SI1273292T1 (en) 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
EP1458360B1 (de) 2001-12-19 2011-05-11 Novartis AG Pulmonale verabreichung von aminoglykosiden
EP1415647A1 (de) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
AU2003259986A1 (en) * 2002-08-23 2004-03-11 Schering Corporation Pharmaceutical compositions
AU2003293528A1 (en) * 2003-02-04 2004-09-06 Chrysalis Technologies Incorporated Perfluorocarbon and hydrofluorocarbon formulations and methods of making and using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8592639B2 (en) * 2004-09-16 2013-11-26 Dsu Medical Corp. Injection and hemostasis site
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
TWI657070B (zh) * 2005-06-24 2019-04-21 美商哈尼威爾國際公司 含有經氟取代之烯烴之組合物及其用途
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
DE102006053374A1 (de) * 2006-02-09 2007-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7825093B2 (en) 2006-10-25 2010-11-02 Amgen Inc. Methods of using OSK1 peptide analogs
WO2008057248A2 (en) 2006-10-26 2008-05-15 Next Breath Llc Phospholipid-based inhalation system
CA2840407A1 (en) 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2077132A1 (de) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Abgabevorrichtung, Aufbewahrungsvorrichtung und Verfahren zur Abgabe einer Formulierung
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
AU2009228093B2 (en) * 2008-03-28 2014-08-07 Neurelis, Inc. Administration of benzodiazepine compositions
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
JP5670421B2 (ja) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンポーネント表面のコーティング方法
EP2432531B1 (de) 2009-05-18 2019-03-06 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
CA2763939A1 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
EP2504051B1 (de) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Zerstäuber
JP5715640B2 (ja) 2009-11-25 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
CA2793170C (en) 2010-03-15 2018-04-17 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
TWI495466B (zh) * 2010-09-23 2015-08-11 Intech Biopharm Ltd 用於氣喘之吸入性複方組合物
CN102416179B (zh) * 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
JP5409594B2 (ja) * 2010-12-22 2014-02-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
EP2675460A4 (de) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc Behandlung von fettgewebe unter dem kinn
JP2014509859A (ja) 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド １７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
PL3415139T3 (pl) 2011-06-14 2022-07-11 Neurelis, Inc. Podawanie benzodiazepiny
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
CN103386125A (zh) * 2012-05-08 2013-11-13 刘江秋 肾综合征出血热鼻黏膜免疫气溶胶疫苗的研制
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3030298B1 (de) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Vernebler
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
CN106255554B (zh) 2014-05-07 2021-05-04 勃林格殷格翰国际有限公司 容器、喷雾器及用途
PL3139984T3 (pl) 2014-05-07 2021-11-08 Boehringer Ingelheim International Gmbh Nebulizator
CN106232166B (zh) 2014-05-07 2020-04-14 勃林格殷格翰国际有限公司 喷雾器
EP2985019B1 (de) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasale Zusammensetzung mit antiviralen Eigenschaften
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3383366B2 (de) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmazeutische zusammensetzung
CA3037080C (en) 2016-09-19 2021-05-18 Mexichem Fluor S.A. De C.V. Stable pharmaceutical compositions comprising indacaterol and 1,1-difluoroethane (hfa-152a) suitable for use in metered dose inhalers (mdis)
BR112019005168A2 (pt) * 2016-09-19 2019-06-11 Mexichem Fluor Sa De Cv composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica
EP3515432B1 (de) 2016-09-19 2021-08-25 Mexichem Fluor S.A. de C.V. Pharmazeutische zusammensetzung enthaltend glycopyrrolate
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
GB2586477A (en) * 2019-08-20 2021-02-24 Mexichem Fluor Sa De Cv Composition and method
WO2023178283A1 (en) 2022-03-18 2023-09-21 Epicentrx, Inc. Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
WO2023215229A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Compositions and methods for treatment of pulmonary hypertension
WO2023215227A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Systems and methods to improve exercise tolerance
WO2023244973A1 (en) 2022-06-13 2023-12-21 Epicentrx, Inc. Compositions and methods for reducing adverse side effects in cancer treatment
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE261096C (de)
BE556587A (de) 1957-01-31 1957-04-11
US2992645A (en) 1958-05-06 1961-07-18 Benger Lab Ltd Disperser for powders
GB1063512A (en) 1962-11-30 1967-03-30 Benger Lab Ltd Aerosols
GB1144905A (en) 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
GB1230472A (de) 1967-07-10 1971-05-05
DE2503962A1 (de) 1975-01-31 1976-08-05 Thomae Gmbh Dr K Spruehbare mittel in suspensionsform zur anwendung auf der haut
GB1554157A (en) 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
DE2750090A1 (de) 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
SE7812207L (sv) 1977-12-01 1979-06-02 Welsh Nat School Med Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer
JPS5529524A (en) 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
JPS6034925B2 (ja) 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS5795920A (en) 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
US4900730A (en) 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US5260306A (en) 1981-07-24 1993-11-09 Fisons Plc Inhalation pharmaceuticals
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4959358A (en) 1983-06-06 1990-09-25 Beth Israel Hospital Assn. Drug administration
US4548922A (en) 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
DE3323389A1 (de) 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
DE3326089A1 (de) 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin Zur inhalation bestimmte darreichungsform von calcium-antagonisten
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4537772A (en) 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IL78425A (en) 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
AU587472B2 (en) 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
US4847298A (en) 1985-08-16 1989-07-11 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4731360A (en) 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US4926852B1 (en) 1986-06-23 1995-05-23 Univ Johns Hopkins Medication delivery system phase one
DE3784594T2 (de) 1986-08-11 1994-01-05 Innovata Biomed Ltd Mikrokapseln enthaltende pharmazeutische Zusammensetzungen.
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
JP2851627B2 (ja) 1987-10-15 1999-01-27 シンテックス（ユー・エス・エイ）インコーポレイテッド 粉末形態ポリプペチド類の経鼻投与
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
EP0458894B1 (de) 1989-02-17 1996-05-15 The Liposome Company, Inc. Lipidhilfstoffe für verabreichung durch die nase und örtliche anwendung
IT8920486A0 (it) 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
DE4003270A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
DE69231991T2 (de) * 1991-06-10 2002-04-04 Schering Corp Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
PT656207E (pt) * 1991-06-10 2001-11-30 Schering Corp Formulacoes de aerossois sem clorofluorocarbonetos
JP3230056B2 (ja) 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド 薬剤のエーロゾル化服用量を形成する装置
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
CA2127877A1 (en) 1992-01-21 1993-07-22 Robert M. Platz Improved process for preparing micronized polypeptide drugs
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
EP0566135A1 (de) 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosale Zubereitungen enthaltend ein Peptid und ein Cytidinderivat
ES2177544T3 (es) 1992-06-12 2002-12-16 Teijin Ltd Polvo ultrafinno para inhalar y metodo para su preparacion.
US5376359A (en) 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
EP0679088B1 (de) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonale abgabe von aktiven fragmenten des parathormons
JPH08509465A (ja) 1993-01-29 1996-10-08 マイリス メディカル コーポレーション ホルモンの肺内送達
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
WO1994023772A2 (en) 1993-04-06 1994-10-27 Minnesota Mining And Manufacturing Company Deagglomerators for dry powder inhalers
FR2705570B1 (fr) 1993-05-25 1995-07-13 Adir Nouvelle formulation d'aérosol médicamentaux à base de fusafungine, son procédé de préparation et les compositions pharmaceutiques qui la contiennent.
US5661130A (en) * 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
GB9314614D0 (en) 1993-07-14 1993-08-25 Minnesota Mining & Mfg Dry powder inhalers
US5349947A (en) 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
DE69432224T2 (de) * 1993-12-02 2003-12-04 Abbott Lab Aerosole als darreichungsform mit cfc-freiem treibmittel
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
AU689217B2 (en) 1994-03-07 1998-03-26 Novartis Ag Methods and compositions for pulmonary delivery of insulin
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide

Also Published As

Publication number Publication date
CN1170356A (zh) 1998-01-14
US6932962B1 (en) 2005-08-23
AU702880B2 (en) 1999-03-11
ATE236617T1 (de) 2003-04-15
JP2006124404A (ja) 2006-05-18
KR100428914B1 (ko) 2004-06-16
TR199501673A1 (tr) 1997-03-21
PL320856A1 (en) 1997-11-10
EE9700138A (et) 1997-12-15
CZ194797A3 (en) 1997-10-15
DE69530325T2 (de) 2004-02-19
CN1088580C (zh) 2002-08-07
CA2206782C (en) 2007-04-03
EP0806940B1 (de) 2003-04-09
IL116460A (en) 2003-10-31
NO972681D0 (no) 1997-06-11
MY131733A (en) 2007-08-30
NZ298169A (en) 1999-09-29
JP4155594B2 (ja) 2008-09-24
CZ288146B6 (en) 2001-05-16
NO318229B1 (no) 2005-02-21
SK81197A3 (en) 1997-11-05
CA2206782A1 (en) 1996-06-27
EP0806940A1 (de) 1997-11-19
JPH10510829A (ja) 1998-10-20
IS4499A (is) 1997-06-05
AU4359396A (en) 1996-07-10
MX9704550A (es) 1997-10-31
HUT77775A (hu) 1998-08-28
FI972655A0 (fi) 1997-06-19
AR002014A1 (es) 1998-01-07
NO972681L (no) 1997-06-11
BR9510510A (pt) 1998-07-07
IL116460A0 (en) 1996-03-31
WO1996019198A1 (en) 1996-06-27
FI972655A (fi) 1997-06-19

Similar Documents

Publication Publication Date Title
DE69530325D1 (de) Aerosol-arzneiformulierungen
IT1293803B1 (it) Formulazioni di aerosol medicinali
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
DK1073417T3 (da) Farmaceutisk aerosolformulering
FI971279A (fi) Lääkkeitä
NO944526D0 (no) Medisinsk aerosolformulering
ID24654A (id) Formulasi farmasi omeprazola
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
DK0934057T3 (da) Medicinske aerosolformuleringer med formoterol
NO981008D0 (no) Farmasöytisk formulering
NO991407D0 (no) Legemiddelaerosolformuleringer som omfatter budesonid
ID16781A (id) Formulasi-formulasi farmasi
TR199501082A2 (tr) Farmasötik formülasyonlar.
ITMI941169A0 (it) Formulazioni farmaceutiche
FI973230A (fi) Uusi farmaseuttinen formulaatio
FI951155A0 (fi) Farmaseuttinen valmiste
FI962738A (fi) Farmaseuttiset koostumukset
NO991430D0 (no) Insektfordrivende formuleringer
SE9404467D0 (sv) Drug formulations
SE9404469D0 (sv) Aerosol formulations
SE9502452D0 (sv) Aerosol formulations
SE9502453D0 (sv) Drug formulations
SE9404195D0 (sv) New pharmaceutical formulation
DK1037604T3 (da) Farmaceutiske aerosolsammensætninger

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings